Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: Geron Corporation

Market Cap 731M 632M 581M 545M 1.02B 70.03B 1.04B 6.9B 2.68B 33.8B 2.75B 2.69B 117B P/E Ratio 2026 *
-57x
P/E Ratio 2027 * 17.5x
Enterprise Value 710M 614M 565M 530M 993M 68.02B 1.01B 6.7B 2.6B 32.83B 2.67B 2.61B 114B EV / Sales 2026 *
3.04x
EV / Sales 2027 * 1.69x
Free-Float
99.92%
Yield 2026 *
-
Yield 2027 * -
1 day+3.64%
1 week-1.72%
Current month-8.80%
1 month-17.99%
3 months-30.06%
6 months-10.94%
Current year-13.64%
1 week 1.08
Extreme 1.08
1.22
1 month 1.08
Extreme 1.08
1.45
Current year 1.08
Extreme 1.08
2.01
1 year 1.04
Extreme 1.04
2.01
3 years 1.04
Extreme 1.04
5.34
5 years 0.99
Extreme 0.9899
5.34
10 years 0.75
Extreme 0.75
6.99
Manager TitleAgeSince
Chief Executive Officer 54 2025-08-06
Director of Finance/CFO 59 2023-09-24
Chief Tech/Sci/R&D Officer - 2025-09-30
Director TitleAgeSince
Director/Board Member 76 2010-05-20
Director/Board Member 72 2012-09-27
Director/Board Member 55 2019-03-25
Date Insider Type Main position Quantity % Market Cap.
05-19Free

Director

220,000 0.0343%
05-19Free

Director

220,000 0.0343%
05-19Free

Chairman

220,000 0.0343%
Change 5-day change 1-year change 3-year change Capi.($)
+3.64%-1.72%-28.75%-68.33% 706M
+1.65%+11.53%+52.68%+112.78% 54.82B
+0.03%-1.80%+49.57%+43.94% 43.27B
+3.93%+1.23%-16.23%-18.04% 21.79B
+5.27%-6.87%+6.37%+388.48% 19.92B
+0.81%-8.38%+12.77%-33.24% 15.67B
+0.53%+6.07%+8.13%-39.59% 15.26B
+1.75%+3.68%+25.82%+178.65% 13.22B
-5.27%+3.89%+90.88%+208.02% 11.58B
-1.74%-1.05%+12.88% - 11.94B
Average +0.61%-1.04%+21.41%+85.85% 20.82B
Weighted average by Cap. +0.71%+1.14%+31.98%+96.95%

Financials

2026 *2027 *
Net sales 234M 202M 186M 174M 327M 22.38B 332M 2.2B 856M 10.8B 877M 858M 37.42B 333M 288M 265M 248M 465M 31.9B 473M 3.14B 1.22B 15.4B 1.25B 1.22B 53.33B
Net income -13.95M -12.05M -11.09M -10.4M -19.5M -1.34B -19.8M -132M -51.12M -645M -52.38M -51.25M -2.23B 46.55M 40.21M 37.01M 34.7M 65.04M 4.46B 66.07M 439M 171M 2.15B 175M 171M 7.45B
Net Debt -20.97M -18.11M -16.67M -15.63M -29.3M -2.01B -29.76M -198M -76.83M -969M -78.72M -77.01M -3.36B -169M -146M -134M -126M -236M -16.18B -240M -1.59B -619M -7.81B -634M -621M -27.05B
Logo Geron Corporation
Geron Corporation is a commercial-stage biopharmaceutical company. The Company develops first-in-class telomerase inhibitor, RYTELO (imetelstat) for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes (lower-risk MDS), with transfusion-dependent (TD) anemia requiring four or more red blood cell units over eight weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents (ESAs). RYTELO is supported by the high unmet need in lower-risk MDS, including the observed benefit of RYTELO in difficult-to-treat subpopulations, such as patients with high transfusion burden and ring sideroblast negative (RS-) patients. It is also engaged in conducting a pivotal Phase III clinical trial of imetelstat in JAK-inhibitor relapsed/refractory myelofibrosis (R/R MF), as well as studies in other myeloid hematologic malignancies.
Employees
258
Date Price Change Volume
26-06-11 1.140 $ +3.64% 31,677,562
26-06-10 1.100 $ -1.79% 14,737,296
26-06-09 1.120 $ -0.88% 13,609,303
26-06-08 1.130 $ -3.42% 11,184,588
26-06-05 1.170 $ -3.31% 9,600,839
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
1.140USD
Average target price
3.400USD
Spread / Average Target
+198.25%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GERN Stock
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!